Author:
Taylor David,Duncan Denise
Abstract
Carbamazepine and valproate are now well established treatments for bipolar affective disorder (BAD). Both drugs are used in the acute treatment of mania and, more frequently, as longer-term mood stabilisers. The British National Formulary (BNF, Vol. 32, 1996) provides information on the use of carbamazepine in the ‘prophylaxis of manic depressive illness' and suggests that the ‘usual range’ of doses is between 400 mg and 600 mg daily. No guidance on the use of valproate in BAD is given in the BNF because the drug is not licensed for this indication in the UK.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular docking and inhibition profiles of some antidepressants on human carbonic anhydrase enzymes;Results in Chemistry;2023-12
2. Pharmacokinetics;The Maudsley Prescribing Guidelines in Psychiatry;2021-12-17
3. Bipolar Disorder;The Maudsley Prescribing Guidelines in Psychiatry;2021-12-17
4. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder;Cochrane Database of Systematic Reviews;2013-10-17
5. Adherence in psychiatry;Irish Journal of Psychological Medicine;2010-03